Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review
Systemic mastocytosis (SM) is a heterogeneous disease characterized by the expansion of mast cells in one or more tissues, frequently characterized by the presence of KITD816V mutation. The updated World Health Organization (WHO) classification of myeloid neoplasms recognizes SM with an associated h...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.819097/full |
| _version_ | 1819364893536550912 |
|---|---|
| author | Enrico Barozzi Enrico Barozzi Cristina Bucelli Federica Irene Grifoni Umberto Gianelli Umberto Gianelli Alessandra Iurlo Daniele Cattaneo Daniele Cattaneo |
| author_facet | Enrico Barozzi Enrico Barozzi Cristina Bucelli Federica Irene Grifoni Umberto Gianelli Umberto Gianelli Alessandra Iurlo Daniele Cattaneo Daniele Cattaneo |
| author_sort | Enrico Barozzi |
| collection | DOAJ |
| description | Systemic mastocytosis (SM) is a heterogeneous disease characterized by the expansion of mast cells in one or more tissues, frequently characterized by the presence of KITD816V mutation. The updated World Health Organization (WHO) classification of myeloid neoplasms recognizes SM with an associated hematological neoplasm (SM-AHN) as a new subtype among the others, which is depicted by the coexistence of SM with another hematological clonal disease. Prognosis is very different among SM patients, while its treatment, although highly personalized, is still challenging. Here we report a case of KITD816V-unmutated SM associated with MDS/MPN successfully treated with imatinib. |
| first_indexed | 2024-12-24T23:06:11Z |
| format | Article |
| id | doaj.art-fc82bd787821420485aa7157fd39a450 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-24T23:06:11Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-fc82bd787821420485aa7157fd39a4502022-12-21T16:35:02ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-01-011110.3389/fonc.2021.819097819097Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature ReviewEnrico Barozzi0Enrico Barozzi1Cristina Bucelli2Federica Irene Grifoni3Umberto Gianelli4Umberto Gianelli5Alessandra Iurlo6Daniele Cattaneo7Daniele Cattaneo8Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, ItalyHematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyHematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDepartment of Pathophysiology and Transplantation, University of Milan, Milan, ItalyDivision of Pathology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyHematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyHematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, ItalySystemic mastocytosis (SM) is a heterogeneous disease characterized by the expansion of mast cells in one or more tissues, frequently characterized by the presence of KITD816V mutation. The updated World Health Organization (WHO) classification of myeloid neoplasms recognizes SM with an associated hematological neoplasm (SM-AHN) as a new subtype among the others, which is depicted by the coexistence of SM with another hematological clonal disease. Prognosis is very different among SM patients, while its treatment, although highly personalized, is still challenging. Here we report a case of KITD816V-unmutated SM associated with MDS/MPN successfully treated with imatinib.https://www.frontiersin.org/articles/10.3389/fonc.2021.819097/fullimatinibsystemic mastocytosisSM-AHNMDS/MPNmyeloid neoplasms |
| spellingShingle | Enrico Barozzi Enrico Barozzi Cristina Bucelli Federica Irene Grifoni Umberto Gianelli Umberto Gianelli Alessandra Iurlo Daniele Cattaneo Daniele Cattaneo Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review Frontiers in Oncology imatinib systemic mastocytosis SM-AHN MDS/MPN myeloid neoplasms |
| title | Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review |
| title_full | Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review |
| title_fullStr | Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review |
| title_full_unstemmed | Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review |
| title_short | Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review |
| title_sort | successful imatinib treatment for systemic mastocytosis associated with myelodysplastic myeloproliferative neoplasm report of a case and literature review |
| topic | imatinib systemic mastocytosis SM-AHN MDS/MPN myeloid neoplasms |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.819097/full |
| work_keys_str_mv | AT enricobarozzi successfulimatinibtreatmentforsystemicmastocytosisassociatedwithmyelodysplasticmyeloproliferativeneoplasmreportofacaseandliteraturereview AT enricobarozzi successfulimatinibtreatmentforsystemicmastocytosisassociatedwithmyelodysplasticmyeloproliferativeneoplasmreportofacaseandliteraturereview AT cristinabucelli successfulimatinibtreatmentforsystemicmastocytosisassociatedwithmyelodysplasticmyeloproliferativeneoplasmreportofacaseandliteraturereview AT federicairenegrifoni successfulimatinibtreatmentforsystemicmastocytosisassociatedwithmyelodysplasticmyeloproliferativeneoplasmreportofacaseandliteraturereview AT umbertogianelli successfulimatinibtreatmentforsystemicmastocytosisassociatedwithmyelodysplasticmyeloproliferativeneoplasmreportofacaseandliteraturereview AT umbertogianelli successfulimatinibtreatmentforsystemicmastocytosisassociatedwithmyelodysplasticmyeloproliferativeneoplasmreportofacaseandliteraturereview AT alessandraiurlo successfulimatinibtreatmentforsystemicmastocytosisassociatedwithmyelodysplasticmyeloproliferativeneoplasmreportofacaseandliteraturereview AT danielecattaneo successfulimatinibtreatmentforsystemicmastocytosisassociatedwithmyelodysplasticmyeloproliferativeneoplasmreportofacaseandliteraturereview AT danielecattaneo successfulimatinibtreatmentforsystemicmastocytosisassociatedwithmyelodysplasticmyeloproliferativeneoplasmreportofacaseandliteraturereview |